Vaccine-induced cross-genotype reactive neutralizing antibodies against hepatitis C virus

Journal of Infectious Diseases

Volumn 204, Issue 8, 2011, Pages 1186-1190

  Meunier, Jean Christophe ^a,e   Gottwein, Judith M ^b,c   Houghton, Michael ^d   Russell, Rodney S ^a,f   Emerson, Suzanne U ^a   Bukh, Jens ^a,b   Purcell, Robert H ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b Mental Health Services CPH   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d UNIVERSITY OF ALBERTA   (Canada)

^e UNIVERSITÉ DE TOURS   (France)

^f MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN E1; GLYCOPROTEIN E2; HEPATITIS C VACCINE; NEUTRALIZING ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DETECTION; ANTIBODY TITER; ARTICLE; CELL CULTURE; CHIMPANZEE; CONTROLLED STUDY; CROSS REACTION; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; NONHUMAN; PRIORITY JOURNAL; TREATMENT OUTCOME; VIRUS PARTICLE;

ANIMALS; ANTIBODIES, NEUTRALIZING; CROSS REACTIONS; FLOW CYTOMETRY; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; PAN TROGLODYTES; RETROSPECTIVE STUDIES; VACCINATION; VACCINES, SYNTHETIC; VIRAL ENVELOPE PROTEINS; VIRAL HEPATITIS VACCINES;

EID: 80052894158     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jir511     Document Type: Article

References (15)

1. Choo QL, Kuo G, Ralston R, et al. Vaccination of chimpanzees against infection by the hepatitis C virus. Proc Natl Acad Sci USA 1994; 91:1294-8. (Pubitemid 24058997)
2. Farci P, Alter HJ, Wong DC, et al. Prevention of hepatitis C virus infection in chimpanzees after antibody-mediated in vitro neutralization. Proc Natl Acad Sci USA 1994; 91:7792-6.
3. Feray C, Gigou M, Samuel D, et al. Incidence of hepatitis C in patients receiving different preparations of hepatitis B immunoglobulins after liver transplantation. Ann Intern Med 1998; 128:810-6. (Pubitemid 28267713)
4. Knodell RG, Conrad ME, Ginsberg AL, Bell CJ. Efficacy of prophylactic gamma-globulin in preventing non-A, non-B post-transfusion hepatitis. Lancet 1976; 1:557-61.
5. Houghton M. Prospects for prophylactic and therapeutic vaccines against the hepatitis C viruses. Immunol Rev 2011; 239:99-108.
6. Mikkelsen M, Bukh J. Current status of a hepatitis C vaccine: encouraging results but significant challenges ahead. Curr Infect Dis Rep 2007; 9:94-101. (Pubitemid 46416050)
7. Dahari H, Feinstone SM, Major ME. Meta-analysis of hepatitis C virus vaccine efficacy in chimpanzees indicates an importance for structural proteins. Gastroenterology 2010; 139:965-74.
8. Coates S, Choo QL, Kuo G, et al. Protection of chimpanzees against heterologous 1a viral challenge using a gpE1/gpE2 heterodimer vaccine. In: Jilbert AR, Grgacic EVL, Vickery K, Burrell CJ, Cossart YE eds. Proceedings of the 11th International Symposium on Viral Hepatitis and Liver Disease, Sydney 2003. Melbourne, Australia: The Australian Centre for Hepatitis Virology, 2003:118-23.
9. Gottwein JM, Scheel TK, Jensen TB, et al. Development and characterization of hepatitis C virus genotype 1-7 cell culture systems: role of CD81 and scavenger receptor class B type I and effect of antiviral drugs. Hepatology 2009; 49:364-77.
10. Meunier JC, Engle RE, Faulk K, et al. Evidence for cross-genotype neutralization of hepatitis C virus pseudo-particles and enhancement of infectivity by apolipoprotein C1. Proc Natl Acad Sci USA 2005; 102:4560-5. (Pubitemid 40397151)
11. Spaete RR, Alexander D, Rugroden ME, et al. Characterization of the hepatitis C virus E2/NS1 gene product expressed in mammalian cells. Virology 1992; 188:819-30.
12. Gottwein JM, Scheel TK, Callendret B, et al. Novel infectious cDNA clones of hepatitis C virus genotype 3a (strain S52) and 4a (strain ED43): genetic analyses and in vivo pathogenesis studies. J Virol 2010; 84:5277-93.
13. Stamataki Z, Coates S, Evans MJ, et al. Hepatitis C virus envelope glycoprotein immunization of rodents elicits cross-reactive neutralizing antibodies. Vaccine 2007; 25:7773-84. (Pubitemid 47588528)
14. + T-cell responses and cross-neutralizing antibodies against hepatitis C virus by vaccination with Th1-adjuvanted polypeptides followed by defective alphaviral particles expressing envelope glycoproteins gpE1 and gpE2 and nonstructural proteins 3, 4, and 5. J Virol 2008; 82:7492-503.
15. Vieyres G, Thomas X, Descamps V, Duverlie G, Patel AH, Dubuisson J. Characterization of the envelope glycoproteins associated with infectious hepatitis C virus. J Virol 2010; 84:10159-68.